TrialCurveATTRACTION-2 (Japanese subgroup): reconstructed Kaplan–Meier curves
A subanalysis of Japanese patients in a randomized, double-blind, placebo-controlled, phase 3 trial of nivolumab for patients with advanced gastric or gastro-esophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2). Curves rebuilt as patient-level data (Guyot 2012) and checked against the statistics printed on the figure.
| Publication | Gastric Cancer. 2018 Dec 1;22(2):344–54. doi: 10.1007/s10120-018-0899-6 |
|---|---|
| DOI | 10.1007/s10120-018-0899-6 |
| Registry | — |
| Phase | — |
| Conditions | — |
| Interventions | — |
| Sponsor | — |
| Enrolment | — |
| Source licence | Figure published under CC BY 4.0 |
Progression-free survival — Japanese ITT population
From figure panel b · validated against the values printed on the figure · curve source: vision model
Reconstructed from the published curve. Median: Nivolumab 1.7 months; Placebo 1.5 months. Survival at 12 months: Nivolumab 9%; Placebo 3%. Hazard ratio Nivolumab vs Placebo 0.56 (95% CI 0.41–0.75).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| Nivolumab | 152 | 135 | 1.7 |
| Placebo | 74 | 70 | 1.5 |
- Nivolumab vs Placebo: reconstructed HR 0.56 (95% CI 0.41–0.75)
Landmark survival (reconstructed)
| Time | Nivolumab | Placebo |
|---|---|---|
| 6 mo | 19.1% | 6.4% |
| 12 mo | 9.5% | 3.2% |
| 18 mo | 5.4% | 1.6% |
| 24 mo | 2.7% | — |
Checks against the published figure
- Nivolumab median: printed 1.7, reconstructed 1.69 pass
- Placebo median: printed 1.5, reconstructed 1.49 pass
- hazard ratio (direction inferred): printed 0.53, reconstructed 0.556 pass
Overall survival — Patients with prior ramucirumab treatment (ITT population)
From figure panel a · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: Nivolumab 5.2 months; Placebo 2.7 months. Survival at 12 months: Nivolumab 28%; Placebo 14%. Hazard ratio Nivolumab vs Placebo 0.56 (95% CI 0.31–1.04).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| Nivolumab | 34 | 24 | 5.2 |
| Placebo | 21 | 18 | 2.7 |
- Nivolumab vs Placebo: reconstructed HR 0.56 (95% CI 0.31–1.04)
Landmark survival (reconstructed)
| Time | Nivolumab | Placebo |
|---|---|---|
| 6 mo | 49.1% | 28.6% |
| 12 mo | 27.6% | 14.3% |
| 18 mo | 27.6% | 14.3% |
| 24 mo | 27.6% | 14.3% |
Checks against the published figure
- Nivolumab median: printed 5.3, reconstructed 5.25 pass
- Placebo median: printed 2.8, reconstructed 2.71 pass
- hazard ratio (direction inferred): printed 0.57, reconstructed 0.564 pass
Overall survival — Patients without prior ramucirumab treatment (ITT population)
From figure panel b · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: Nivolumab 5.4 months; Placebo 3.9 months. Survival at 12 months: Nivolumab 28%; Placebo 15%. Hazard ratio Nivolumab vs Placebo 0.64 (95% CI 0.45–0.91).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| Nivolumab | 118 | 96 | 5.4 |
| Placebo | 53 | 49 | 3.9 |
- Nivolumab vs Placebo: reconstructed HR 0.64 (95% CI 0.45–0.91)
Landmark survival (reconstructed)
| Time | Nivolumab | Placebo |
|---|---|---|
| 6 mo | 46.6% | 36.6% |
| 12 mo | 27.7% | 15.4% |
| 18 mo | 18.4% | 5.8% |
| 24 mo | 14.2% | 5.8% |
Checks against the published figure
- Nivolumab median: printed 5.5, reconstructed 5.37 pass
- Placebo median: printed 3.9, reconstructed 3.91 pass
- hazard ratio (direction inferred): printed 0.65, reconstructed 0.641 pass
Progression-free survival — Patients with prior ramucirumab treatment (ITT population)
From figure panel c · validated against the values printed on the figure · curve source: vision model
Reconstructed from the published curve. Median: Nivolumab 3.0 months; Placebo 1.4 months. Survival at 12 months: Nivolumab 16%; Placebo 5%. Hazard ratio Nivolumab vs Placebo 0.38 (95% CI 0.21–0.70).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| Nivolumab | 34 | 26 | 3.0 |
| Placebo | 21 | 21 | 1.4 |
- Nivolumab vs Placebo: reconstructed HR 0.38 (95% CI 0.21–0.70)
Landmark survival (reconstructed)
| Time | Nivolumab | Placebo |
|---|---|---|
| 6 mo | 26.3% | 4.8% |
| 12 mo | 15.8% | 4.8% |
| 18 mo | 15.8% | 4.8% |
| 24 mo | 15.8% | — |
Checks against the published figure
- Nivolumab median: printed 3, reconstructed 2.95 pass
- Placebo median: printed 1.4, reconstructed 1.37 pass
- hazard ratio (direction inferred): printed 0.39, reconstructed 0.384 pass
Progression-free survival — Patients without prior ramucirumab treatment (ITT population)
From figure panel d · validated against the values printed on the figure · curve source: vision model
Reconstructed from the published curve. Median: Nivolumab 1.6 months; Placebo 1.5 months. Survival at 6 months: Nivolumab 17%; Placebo 7%. Hazard ratio Nivolumab vs Placebo 0.62 (95% CI 0.44–0.87).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| Nivolumab | 118 | 108 | 1.6 |
| Placebo | 53 | 50 | 1.5 |
- Nivolumab vs Placebo: reconstructed HR 0.62 (95% CI 0.44–0.87)
Landmark survival (reconstructed)
| Time | Nivolumab | Placebo |
|---|---|---|
| 6 mo | 17.1% | 6.8% |
| 12 mo | 7.6% | 2.3% |
| 18 mo | 3.6% | — |
Checks against the published figure
- Nivolumab median: printed 1.6, reconstructed 1.64 pass
- Placebo median: printed 1.5, reconstructed 1.49 pass
- hazard ratio (direction inferred): printed 0.64, reconstructed 0.619 pass
About these data
Pseudo-IPD reproduces the published curves and numbers at risk; the rows are not real patients. Cite the publication (DOI above) and TrialCurve. The source figure is © the authors (CC BY 4.0); the charts here are redrawn from the reconstruction.
Load these data in R or Python
# R
library(survival)
d <- read.csv("https://trialcurve.com/data/trials/attraction-2-japanese-subgroup-1.csv")
survfit(Surv(time, event) ~ arm, data = d)
coxph(Surv(time, event) ~ arm, data = d)
# Python
import pandas as pd
from lifelines import KaplanMeierFitter
d = pd.read_csv("https://trialcurve.com/data/trials/attraction-2-japanese-subgroup-1.csv")
for arm, g in d.groupby("arm"):
KaplanMeierFitter().fit(g.time, g.event, label=arm).plot_survival_function()
Suggested citation: Gastric Cancer. 2018 Dec 1;22(2):344–54. doi: 10.1007/s10120-018-0899-6 doi:10.1007/s10120-018-0899-6. Reconstructed data: TrialCurve (2026), https://trialcurve.com/trials/attraction-2-japanese-subgroup
Report a problem with these data
Related trials
- ATTRACTION-2 (prior trastuzumab subgroup): Overall survival; Progression-free survival
- ATTRACTION-2 (2-year update): Overall survival; Progression-free survival
- JACOB (Chinese subgroup): Overall survival; Progression-free survival (investigator-assessed)
- Gastrectomy and second-line chemotherapy in advanced gastric cancer: Overall survival; Overall survival (IPTW-adjusted); Progression-free survival; Progression
- KEYNOTE-590 (Japanese subgroup, extended follow-up): Overall survival; Progression-free survival
- Preoperative chemoradiotherapy vs chemotherapy in gastric/GEJ cancer: Disease-free survival; Overall survival
Need reconstructed data for other trials? Upload any Kaplan–Meier figure, or ask about the TrialCurve oncology library.
Reconstruct a figure Browse all trials